How should an adult with elevated white blood cell count and elevated platelet count be evaluated?

Evaluation of Elevated WBC and Platelet Count

Begin by obtaining a repeat complete blood count with differential and peripheral blood smear to confirm persistent elevations and assess for myeloproliferative neoplasms, followed by targeted testing for secondary causes and JAK2 mutation if primary thrombocytosis is suspected 1.

Initial Diagnostic Approach

Confirm the Abnormality

• Repeat CBC with differential within 1-2 weeks to verify persistent elevations and rule out laboratory artifact 1
• Peripheral blood smear is essential to evaluate:
  • Platelet clumping (which can cause spurious WBC elevation) 2
  • Morphologic abnormalities suggesting myeloproliferative neoplasms
  • Left shift or immature cells
  • Red blood cell morphology

Risk Stratification for Myeloproliferative Neoplasms

The combination of elevated WBC and platelets raises concern for myeloproliferative neoplasms (MPNs), particularly essential thrombocythemia (ET) or polycythemia vera (PV). According to NCCN guidelines, age >60 years and prior thrombosis history are the most critical risk factors for thrombotic complications 3.

Secondary Workup

Rule Out Reactive Causes First

Order the following tests based on clinical context:

• C-reactive protein (CRP) - to assess for inflammatory/infectious processes 1
• Iron studies with ferritin - iron deficiency is a common cause of reactive thrombocytosis 1
• Assess for:
  • Active infection (pneumonia, urinary tract infection, abscess)
  • Inflammatory conditions (rheumatologic disease, inflammatory bowel disease)
  • Malignancy (particularly solid tumors)
  • Recent surgery or trauma
  • Medications (corticosteroids, growth factors)
  • Metabolic syndrome features 4, 5

Important caveat: In infectious conditions, platelet counts typically increase alongside WBC, but this is usually modest and resolves with treatment 6. Persistent elevation after treating the underlying cause warrants further investigation.

Evaluation for Primary Myeloproliferative Neoplasms

When to Suspect Essential Thrombocythemia or Polycythemia Vera

Proceed with MPN workup if:

• Platelet count ≥450 × 10³/μL persists without identified secondary cause 1
• Associated findings: splenomegaly, microvascular symptoms (headaches, paresthesias, erythromelalgia), unexplained thrombosis or bleeding 1
• Leukocytosis persists (particularly >10 × 10⁹/L) 3

Molecular Testing Sequence

1. JAK2 V617F mutation testing - first-line molecular test 1

• If positive: strongly suggests MPN (found in ~95% of PV, ~60% of ET)

2. If JAK2 negative:

• Calreticulin (CALR) mutation 1
• Myeloproliferative leukemia (MPL) mutation 1

3. Bone marrow biopsy - required for definitive diagnosis of ET 1

Risk Stratification for Essential Thrombocythemia

Use the revised International Prognostic Score of Thrombosis for ET (IPSET-Thrombosis) 3, 1:

Very Low-Risk

• Age ≤60 years
• No JAK2 mutation
• No prior thrombosis
• Management: Observation, cardiovascular risk factor modification 3

Low-Risk

• Age ≤60 years
• JAK2 mutation present
• No prior thrombosis
• Management: Low-dose aspirin (81-100 mg/day) for vascular symptoms or observation 3

High-Risk

• Age >60 years and/or prior thrombosis history
• Management: Cytoreductive therapy (hydroxyurea first-line) plus low-dose aspirin 3, 1

Treatment Considerations

Indications for Cytoreductive Therapy in ET/PV

Initiate cytoreductive therapy for 3:

• High-risk patients (age >60 or prior thrombosis)
• New thrombosis
• Symptomatic or progressive splenomegaly
• Progressive leukocytosis
• Vasomotor symptoms not responsive to aspirin
• Acquired von Willebrand disease with bleeding

First-Line Cytoreductive Agent

Hydroxyurea is the standard first-line agent 3, 1. Target platelet count <400 × 10⁹/L for ET 7.

Alternative agents:

• Interferon alfa-2b or peginterferon alfa-2a/2b (preferred in younger patients or pregnancy) 3
• Anagrelide (second-line, inferior to hydroxyurea) 3

Critical Pitfalls to Avoid

1. Don't dismiss as reactive without adequate workup - Persistent unexplained thrombocytosis with leukocytosis requires MPN evaluation
2. Check for EDTA-dependent pseudothrombocytopenia - Can cause spurious WBC elevation in 92% of cases 2
3. Don't delay anticoagulation if thrombosis occurs - Use appropriate anticoagulation per ACCP guidelines while initiating cytoreductive therapy 3
4. Extreme thrombocytosis (>1,000 × 10⁹/L) increases bleeding risk, not thrombosis risk 3 - may require plateletpheresis in acute settings
5. Monitor for transformation - MPNs can progress to myelofibrosis or acute leukemia

Special Populations

• Metabolic syndrome patients may have modest elevations in both WBC and platelets as inflammatory markers 4, 5 - typically not to MPN levels
• Post-splenectomy patients normally have elevated WBC and platelets; WBC >15 × 10³/μL on postoperative day 5 suggests infection 8